

[Dr. Gail Brown](#), M.D, M.B.A, began her career at Harvard Medical School, where she served on the faculty of the Department of Medicine, Division of Hematology and Oncology. She holds an M.D. degree from the University of Rochester School of Medicine and an M.B.A. degree from St. Mary's College of California Graduate School of Economics and Business Administration. She received her postdoctoral training in medicine at the Peter Bent Brigham, medical oncology fellowship at the Dana Farber Cancer Institute, and postdoctoral research fellowship at the M.I.T. Center for Cancer Research as a Helen Hay Whitney Fellow.

In 2016, Dr. Brown joined ARMO BioSciences, Inc., a late-stage immuno-oncology company as their Chief Medical Officer. Dr. Brown has advanced the lead clinical program with PEG-IL-10 from Phase 1 to Phase 3. ARMO BioSciences filed an IPO and 4 months later was purchased by Ely Lilly, Inc. Prior to joining ARMO BioSciences, Dr. Brown served as Senior Medical Director at AbbVie and worked on the Venetoclax hematological malignancies programs.

Prior to joining RRD, Gail served as Senior Vice President and Chief Medical Officer of Telik, Inc. from 2001 until July 2014. Dr. Brown is and performed as an experienced fiscal and operational executive with over 20 years of progressively responsible experience in the biotechnology industry. A detail-oriented forward-thinker adept at driving and facilitating growth, Dr. Brown has earned a reputation for building clinical research organizations. She has consistently demonstrated strong fundraising, strategic, analytical, negotiation, communication, and problem-solving abilities in both start-up environments and in publicly traded companies.

Before joining Telik, Dr. Brown was affiliated with several investment organizations specializing in the biotechnology industry and served as a consultant and member of clinical and scientific advisory boards at numerous public and private biotechnology companies. While at Telik, Inc., Dr. Brown participated in drafting prospectuses and in raising over \$500 million through an IPO and subsequent follow-on offerings. She helped expand the clinical group at Telik from four to 100 employees. Dr. Brown has extensive speaking experience at national biotechnology panels, investment banking biotechnology meetings, and scientific peer-reviewed meetings; she also speaks with biotechnology research analysts for company research coverage.

Dr. Brown provided financial consulting services as a partner in Altair Capital Associates, LLC, which she co-founded in November 1998. In 2000, she joined the Paladin Group LLC as one of five managing directors, overseeing a billion-dollar hedge fund that invested in private equity financings in publicly traded biotechnology companies. Dr. Brown was one of two managing directors of investments in a start-up venture fund spin-off from Paladin, named the Tanager Capital Group LLC, in 2000.